IO Therapy in mCRPC and Clinical Pearls
Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.
Read More
Practical Application of PARP Inhibitors in Metastatic CRPC
Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.
Read More
Metastatic CRPC: Advent of PARP Inhibitors
Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.
Read More
Overview of the Metastatic Castration-Resistant Prostate Cancer Treatment Paradigm
Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).
Read More
Novel Treatment Modalities in Metastatic Hormone-Sensitive Prostate Cancer
Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.
Read More
Educating Patients on Treatment Options in Metastatic HSPC
Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.
Read More
Metastatic Hormone-Sensitive Prostate Cancer: Data from TITAN and PEACE-1
Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.
Read More
Metastatic Hormone-Sensitive Prostate Cancer: Data From ENZAMET and ARCHES
Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.
Read More
Metastatic Hormone-Sensitive Prostate Cancer: Data From ARASENS and ARANOTE
A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.
Read More
Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.
Read More
Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer
A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.
Read More
Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate Cancer
Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.
Read More
Optimizing Care for Patients With Non-metastatic CRPC
Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.
Read More
Non-metastatic Castration-Resistant Prostate Cancer: Patient Monitoring Strategies
Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.
Read More
Importance of Quality of Life When Choosing Therapy for nmCRPC
A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.
Read More
AR Inhibitors in nmCRPC: Real-World Data
Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.
Read More
nmCRPC: Clinical Trial Data on AR Inhibitors
Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.
Read More
Goals of Treatment for Non-metastatic Castration-Resistant Prostate Cancer
Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
Read More
Key Unmet Needs in Prostate Cancer Management
Before centering discussion on subsets of prostate cancer, panelists consider general challenges and unmet needs within the treatment landscape.
Read More
Dr. Posadas Discusses Cabozantinib in Prostate Cancer
June 11th 2014Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer(mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.
Read More